Esopen LS Capsule ER is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dyspepsia with associated motility disturbances. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as bloating, nausea, and abdominal discomfort. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, promoting mucosal healing and reducing acid-related irritation. The extended-release (ER) formulation ensures sustained therapeutic plasma concentrations, improving patient compliance through once-daily dosing. Esopen LS Capsule ER is indicated for patients requiring combined acid suppression and prokinetic therapy, particularly in cases where delayed gastric emptying complicates acid reflux symptoms. It should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, and consideration given to potential drug interactions and contraindications. Regular monitoring is recommended to assess therapeutic response and detect adverse effects such as extrapyramidal symptoms or electrolyte imbalances.